| SPIRIT-P1 and SPIRIT-P2 | |
---|---|---|
IXE Q4W (N = 229) | IXE Q2W (N = 226) | |
Patients with stable MTX dose, n (%) | 85 (37.1) | 98 (43.4) |
Overall average dose, mg/week | 15.7 | 16.0 |
Route of MTX administration: | ||
 Intramuscular, n (%) | 1 (1.2) | 2 (2.0) |
 Average dose, mg/week | 25.0 | 12.5 |
 Subcutaneous, n (%) | 14 (16.5) | 15 (15.3) |
 Average dose, mg/week | 17.7 | 19.7 |
 Oral, n (%) | 70 (82.4) | 81 (82.7) |
 Average dose, mg/week | 15.2 | 15.4 |